FCF/Share TTM
The latest quarterly fcf/share ttm is $5.87 with a quarterly period change of +9.86%. Free cash flow per share divides trailing free cash flow by shares outstanding, showing cash generation per share.
PODD FCF/Share TTM
Rolling trailing-12-month free cash flow per share; no daily interpolation.
Quarterly FCF/Share TTM History
| Period | FCF/Share TTM | % Change |
|---|---|---|
| Q1 2026 | $5.87 | +9.86% |
| Q4 2025 | $5.34 | (10.34%) |
| Q3 2025 | $5.96 | +8.44% |
| Q2 2025 | $5.50 | +45.86% |
| Q1 2025 | $3.77 | (4.19%) |
| Q4 2024 | $3.93 | +17.82% |
| Q3 2024 | $3.34 | +18.07% |
| Q2 2024 | $2.83 | +22.45% |
| Q1 2024 | $2.31 | +130.15% |
| Q4 2023 | $1.00 | +599.17% |
| Q3 2023 | ($0.20) | +44.92% |
| Q2 2023 | ($0.36) | +43.52% |
| Q1 2023 | ($0.65) | (18.15%) |
| Q4 2022 | ($0.55) | +39.73% |
| Q3 2022 | ($0.91) | +55.30% |
| Q2 2022 | ($2.03) | +6.64% |
| Q1 2022 | ($2.17) | +20.44% |
| Q4 2021 | ($2.73) | +4.44% |
| Q3 2021 | ($2.86) | (50.90%) |
| Q2 2021 | ($1.90) | (4.50%) |
| Q1 2021 | ($1.81) | (45.14%) |
| Q4 2020 | ($1.25) | (468.36%) |
| Q3 2020 | ($0.22) | +39.91% |
| Q2 2020 | ($0.37) | +63.68% |
| Q1 2020 | ($1.01) | +9.66% |
| Q4 2019 | ($1.11) | +4.26% |
| Q3 2019 | ($1.16) | +30.32% |
| Q2 2019 | ($1.67) | +18.70% |
| Q1 2019 | ($2.06) | +0.71% |
| Q4 2018 | ($2.07) | +2.40% |
| Q3 2018 | ($2.12) | (33.61%) |
| Q2 2018 | ($1.59) | (229.92%) |
| Q1 2018 | ($0.48) | +22.19% |
| Q4 2017 | ($0.62) | (219.53%) |
| Q3 2017 | ($0.19) | +69.17% |
| Q2 2017 | ($0.63) | +9.53% |
| Q1 2017 | ($0.69) | (542.52%) |
| Q4 2016 | ($0.11) | +86.37% |
| Q3 2016 | ($0.79) | (58.50%) |
| Q2 2016 | ($0.50) | +1.69% |
| Q1 2016 | ($0.51) | (25.02%) |
| Q4 2015 | ($0.41) | (2697.74%) |
| Q3 2015 | $0.02 | +124.60% |
| Q2 2015 | ($0.06) | +50.23% |
| Q1 2015 | ($0.13) | (179.96%) |
| Q4 2014 | ($0.05) | +76.49% |
| Q3 2014 | ($0.19) | (0.76%) |
| Q2 2014 | ($0.19) | (118.44%) |
| Q1 2014 | ($0.09) | (21.94%) |
| Q4 2013 | ($0.07) | +25.58% |
| Q3 2013 | ($0.10) | +65.78% |
| Q2 2013 | ($0.28) | +52.44% |
| Q1 2013 | ($0.60) | +28.02% |
| Q4 2012 | ($0.83) | +5.77% |
| Q3 2012 | ($0.88) | (10.00%) |
| Q2 2012 | ($0.80) | (4.79%) |
| Q1 2012 | ($0.76) | +0.82% |
| Q4 2011 | ($0.77) | +2.03% |
| Q3 2011 | ($0.79) | +23.38% |
| Q2 2011 | ($1.03) | (9.73%) |
| Q1 2011 | ($0.94) | (1.17%) |
| Q4 2010 | ($0.93) | +12.76% |
| Q3 2010 | ($1.06) | (0.78%) |
| Q2 2010 | ($1.05) | +19.61% |
| Q1 2010 | ($1.31) | +5.47% |
| Q4 2009 | ($1.38) | +34.28% |
| Q3 2009 | ($2.11) | +18.26% |
| Q2 2009 | ($2.58) | +17.05% |
| Q1 2009 | ($3.11) | +6.75% |
| Q4 2008 | ($3.33) | +0.72% |
| Q3 2008 | ($3.36) | (10.70%) |
| Q2 2008 | ($3.03) | (26.51%) |
| Q1 2008 | ($2.40) | (8.59%) |
| Q4 2007 | ($2.21) | (3.98%) |
| Q3 2007 | ($2.12) | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy